Mitchell David Burnbaum, MD Psychiatry & Neurology - Neurology Medicare: Medicare Enrolled Practice Location: 551 Kokopelli Blvd Unit G, Fruita, CO 81521 Phone: 970-243-9180 Fax: 970-245-2697 |
News Archive
SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, today announced that patient enrollment was completed in March in its dermaPACE™ Phase III pivotal, randomized, double-blinded, sham controlled, multicenter clinical trial comparing its Pulsed Acoustic Cellular Expression technology, utilizing the dermaPACE™ tissue regeneration device, to sham control for the treatment of diabetic foot ulcers.
Biotie has started a clinical trial with its phosphodiesterase 4 (PDE4) inhibitor ELB353, having received the prerequisite regulatory and ethical clearances for the clinical trial application.
The U.S. Department of Health and Human Services today announced a series of initiatives to work with states to save money and better coordinate care for the 9 million Americans enrolled in both Medicare and Medicaid.
Many people with cystic fibrosis develop diabetes. The reasons for this have been largely unknown, but now researchers at Lund University in Sweden and Karolinska institutet have identified a molecular mechanism that contributes to the raised diabetes risk.
NPR's "Shots" blog examines the "test and treat" approach to HIV care and prevention, which "relies on the fact that taking HIV drugs dramatically reduces a person's risk of transmitting the virus to others," and, "[a]s more and more people are put on medication, the epidemic theoretically should fizzle out." The blog continues, "Test and treat sounds good on paper, but some doctors and policymakers have doubts about its feasibility on a large scale."
› Verified 8 days ago